Spoken Alpha
Quantum Cyber N.V.
Quantum Cyber N.V. develops in-vitro diagnostic blood and stool tests for early detection of pancreatic cancer, having recently acquired exclusive rights to mRNA biomarkers and an AI algorithm for pancreatic cancer screening.
Quantum Cyber N.V is a Healthcare company operating in Diagnostics & Research with a $35.1M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 20, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add QUCY, reply to your welcome email and we'll prioritize it.
History
Spoken Alpha tracks QUCY's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for QUCY.
$ curl https://api.spokenalpha.com/v1/companies/QUCYFAQ
Spoken Alpha indexes QUCY's earnings call transcripts at https://spokenalpha.com/companies/QUCY. Each call links to attributed speakers and parsed analyst Q&A. Quantum Cyber N.V.'s own investor relations page is at https://quantum-cyber.ai/investors/stock-information.
Quantum Cyber N.V. (QUCY) operates in the Healthcare sector (Diagnostics & Research industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-20 | — | — | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-17 | $-0.43 | — | — | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-04-08 | $-9.80 | — | — | — | — | — | EODHD |
| Q3 FY2023 | 2023-11-15 | $-15.78 | — | — | — | — | — | EODHD |
| Q2 FY2023 | 2023-08-14 | $-22.13 | — | — | — | — | — | EODHD |
| Q1 FY2023 | 2023-05-15 | $-17.87 | — | — | — | — | — | EODHD |
Source: EODHD. QUCY reported actuals as published; sparse fields render as —.
Repeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.91 | $0.97 | -6.1% | 0.0% | -0.6% |
| Q4 FY2026 | $0.84 | $0.98 | -13.9% | +5.1% | +2.8% |
| Q3 FY2026 | $0.94 | $1.03 | -8.8% | +5.7% | +4.5% |
| Q2 FY2026 | $0.84 | $0.99 | -15.3% | +3.9% | +1.7% |
| Q1 FY2025 | $0.83 | $1.01 | -18.0% | -3.4% | -4.9% |
CEO since 2026 • 1/2 beats (50%) • guidance suspended Q1 FY2026
| Q4 FY2025 | $0.83 | $1.01 | -17.5% | -3.5% | -6.4% |
| Q3 FY2025 | $1.05 | $1.12 | -6.2% | -1.6% | -4.5% |
| Q2 FY2025 | $1.00 | $1.26 | -20.7% | +1.9% | +2.8% |
| Q1 FY2024 | $1.06 | $1.25 | -14.9% | +2.4% | +4.8% |
| Q4 FY2024 | $1.01 | $1.21 | -16.7% | +4.6% | +6.9% |